- Home
- AISPW vs TNGX Comparison
AISPW vs TNGX Comparison
Compare AISPW & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AISPW
- TNGX
- Stock Information
- Founded
- AISPW 2006
- TNGX 2014
- Country
- AISPW United States
- TNGX United States
- Employees
- AISPW N/A
- TNGX N/A
- Industry
- AISPW Blank Checks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- AISPW Finance
- TNGX Health Care
- Exchange
- AISPW Nasdaq
- TNGX Nasdaq
- Market Cap
- AISPW N/A
- TNGX 351.2M
- IPO Year
- AISPW N/A
- TNGX N/A
- Fundamental
- Price
- AISPW $1.93
- TNGX $6.73
- Analyst Decision
- AISPW
- TNGX Strong Buy
- Analyst Count
- AISPW 0
- TNGX 6
- Target Price
- AISPW N/A
- TNGX $12.20
- AVG Volume (30 Days)
- AISPW 97.7K
- TNGX 2.5M
- Earning Date
- AISPW 04-02-2025
- TNGX 08-06-2025
- Dividend Yield
- AISPW N/A
- TNGX N/A
- EPS Growth
- AISPW N/A
- TNGX N/A
- EPS
- AISPW N/A
- TNGX N/A
- Revenue
- AISPW $17,978,226.00
- TNGX $40,990,000.00
- Revenue This Year
- AISPW N/A
- TNGX N/A
- Revenue Next Year
- AISPW N/A
- TNGX N/A
- P/E Ratio
- AISPW N/A
- TNGX N/A
- Revenue Growth
- AISPW N/A
- TNGX 10.09
- 52 Week Low
- AISPW $0.18
- TNGX $1.03
- 52 Week High
- AISPW $3.00
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- AISPW N/A
- TNGX 75.80
- Support Level
- AISPW N/A
- TNGX $5.75
- Resistance Level
- AISPW N/A
- TNGX $6.40
- Average True Range (ATR)
- AISPW 0.00
- TNGX 0.47
- MACD
- AISPW 0.00
- TNGX 0.02
- Stochastic Oscillator
- AISPW 0.00
- TNGX 89.51
About AISPW Airship AI Holdings Inc.
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.